Class: Central Nervous System
Dosage Form: Tablets
Description: Dopamine agonist anti-parkinsonian agent
Manufacturer: Eva Pharma
Pramipexole dihydrochloride monohydrate…………..0.25 or 1 mg
Pramipexole dihydrochloride – a benzothiazolamine derivative – is a non-ergot dopamine receptor agonist. Its action is through mimicking brain activities of a PD patient who would otherwise normally respond to dopamine. Pramipexole may be used with or without levodopa and has been shown to be effective in delaying the development of levodopa-associated motor fluctuations and dyskinesias
Ramixole is contraindicated in case of hypersensitivity to any of the product ingredients.
The following interactions are to be noted:
- When combined with levodopa/carbidopa pramipexole caused an earlier Tmax for levodopa but resulted in no changes in the extent of levodopa absorption or elimination
- Avoid concomitant use of antipsychotic
- Excretion of pramipexole reduced by cimetidine
- Effects of dopaminergics possibly enhanced by memantine
Dosage and Administration:
Dosage reduction should be adjusted by physician in renal and hepatic impairment, in psychotic disorders, in severe cardiovascular diseases and in pregnancy.
Caution should be exerted in patients who experience symptoms of sleepiness and somnolence when driving or operating machinery.
Boxes of one or two blisters each containing 10 tablets.
Store at room temperature, below 25°C.